Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT

Cancer

Volumn 123, Issue 11, 2017, Pages 1965-1970

  Pavlů, Jiří ^a   Labopin, Myriam ^b   Zoellner, Anna K ^c   Sakellari, Ioanna ^d   Stelljes, Matthias ^e   Finke, Jürgen ^f   Fanin, Renato ^g   Stuhler, Gernot ^h   Afanasyev, Boris V ⁱ   Bloor, Adrian J ^j   Anagnostopoulos, Achilles ^d   Mohty, Mohamad ^b   Giebel, Sebastian ^k   Nagler, Arnon ^l  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HÔPITAL SAINT ANTOINE   (France)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d G PAPANICOLAOU HOSPITAL   (Greece)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY OF UDINE   (Italy)

^h DKD Helios Clinic Wiesbaden   (Germany)

ⁱ PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^j CHRISTIE HOSPITAL   (United Kingdom)

^k INSTITUTE OF ONCOLOGY   (Poland)

^l SHEBA MEDICAL CENTER   (Israel)

more..

Author keywords

acute lymphoblastic leukemia (ALL); allogeneic transplantation; conditioning regimen; refractory disease; stem cell transplantation; total body irradiation

Indexed keywords

ALEMTUZUMAB; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE REGISTRY; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; T CELL DEPLETION; WHOLE BODY RADIATION; ADOLESCENT; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; PROGNOSIS; REMISSION; TRANSPLANTATION CONDITIONING; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 85013433857     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30604     Document Type: Article

References (19)

1. Forman SJ, Schmidt GM, Nademanee AP, et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol. 1991;9:1570–1574.
2. Biggs JC, Horowitz MM, Gale RP, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood. 1992;80:1090–1093.
3. Fung HC, Stein A, Slovak MI, et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant. 2003;9:766–771.
4. Michallet M, Thomas X, Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant. 2000;26:1157–1163.
5. Craddock C, Labopin M, Pillai S, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia. 2011;25:808–813.
6. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
7. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant. 2001;28:909–915.
8. Aoudjhane M, Labopin M, Gorin NC, et al; Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19:2304–2312.
9. Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:3730–3738.
10. Nagler A, Savani BN, Labopin M, et al. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. Lancet Haematol. 2015;2:e384–e392.
11. Cahu X, Labopin M, Giebel S, et al; Acute Leukemia Working Party of EBMT. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2016;51:351–357.
12. Granados E, de La Camara R, Madero L, et al. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation. Haematologica. 2000;85:1060–1067.
13. Eroglu C, Pala C, Kaynar L, et al. Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2013;54:2474–2479.
14. Gahrton G, Iacobelli S, Apperley J, et al. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant. 2005;35:609–617.
15. Gratwohl A, Hermans J, Niederwieser D, et al; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation EBMT. Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J. 2001;2:363–370.
16. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103:347–352.
17. Giebel S, Czyz A, Ottmann O, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122:2941–2951.
18. Alcharakh M, Yun S, Dong Y, et al. Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia. Immunotherapy. 2016;8:847–852.
19. ClinicalTrials.gov. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for patients with acute lymphoblastic leukemia. https://clinicaltrials.gov/ct2/show/NCT02807883?term=blinatumomab&rank=3. Accessed January 18, 2017.